AAAAAA
Results:
1-21
|
Results: 21
Authors:
Sramek, JJ
Veroff, AE
Cutler, NR
Citation: Jj. Sramek et al., The status of ongoing trials for mild cognitive impairment, EXPERT OP I, 10(4), 2001, pp. 741-752
Authors:
Cutler, NR
Sramek, JJ
Citation: Nr. Cutler et Jj. Sramek, Review of the next generation of Alzheimer's disease therapeutics: Challenges for drug development, PROG NEUR-P, 25(1), 2001, pp. 27-57
Authors:
Salazar, DE
Frackiewicz, EJ
Dockens, R
Kollia, G
Fulmor, IE
Tigel, PD
Uderman, HD
Shiovitz, TM
Sramek, JJ
Cutler, NR
Citation: De. Salazar et al., Pharmacokinetics and tolerability of buspirone during oral administration to children and adolescents with anxiety disorder and normal healthy adults, J CLIN PHAR, 41(12), 2001, pp. 1351-1358
Authors:
Gobburu, JVS
Tammara, V
Lesko, L
Jhee, SS
Sramek, JJ
Cutler, NR
Yuan, RH
Citation: Jvs. Gobburu et al., Pharmacokinetic-pharmacodynamic modeling of rivastigmine, a cholinesteraseinhibitor, in patients with Alzheimer's disease, J CLIN PHAR, 41(10), 2001, pp. 1082-1090
Authors:
Sramek, JJ
Cutler, NR
Citation: Jj. Sramek et Nr. Cutler, Ongoing trials in Alzheimer's disease, EXPERT OP I, 9(4), 2000, pp. 899-915
Authors:
Sramek, JJ
Frackiewicz, EJ
Cutler, NR
Citation: Jj. Sramek et al., Review of the acetylcholinesterase inhibitor galanthamine, EXPERT OP I, 9(10), 2000, pp. 2393-2402
Authors:
Sramek, JJ
Veroff, AE
Cutler, NR
Citation: Jj. Sramek et al., Mild cognitive impairment: Emerging therapeutics, ANN PHARMAC, 34(10), 2000, pp. 1179-1188
Authors:
Frackiewicz, EJ
Sramek, JJ
Cutler, NR
Citation: Ej. Frackiewicz et al., Gender differences in depression and antidepressant pharmacokinetics and adverse events, ANN PHARMAC, 34(1), 2000, pp. 80-88
Authors:
Sramek, JJ
Cutler, NR
Citation: Jj. Sramek et Nr. Cutler, RBC cholinesterase inhibition: A useful surrogate marker for cholinesterase inhibitor activity in Alzheimer disease therapy?, ALZ DIS A D, 14(4), 2000, pp. 216-227
Authors:
Cutler, NR
Sramek, JJ
Greenblatt, DJ
Chaikin, P
Collins, J
Citation: Nr. Cutler et al., Defining the maximum tolerated dose: An update, J CLIN PHAR, 40(11), 2000, pp. 1183-1183
Authors:
Cutler, NR
Sramek, JJ
Citation: Nr. Cutler et Jj. Sramek, Investigator perspective on MTD: Practical application of an MTD definition - Has it accelerated development?, J CLIN PHAR, 40(11), 2000, pp. 1184-1187
Authors:
Sramek, JJ
Hussey, EK
Clements, B
Cutler, NR
Citation: Jj. Sramek et al., Oral sumatriptan pharmacokinetics in the migraine state, CLIN DRUG I, 17(2), 1999, pp. 137-144
Authors:
Sramek, JJ
Anand, R
Hartman, RD
Schran, HF
Hourani, J
Barto, S
Wardle, TS
Shiovitz, TM
Cutler, NR
Citation: Jj. Sramek et al., A bioequivalence study of brand and generic clozapine in patients with schizophrenia - Pharmacokinetic and tolerability findings, CLIN DRUG I, 17(1), 1999, pp. 51-58
Authors:
Sramek, JJ
Cutler, NR
Citation: Jj. Sramek et Nr. Cutler, Recent developments in the drug treatment of Alzheimer's disease, DRUG AGING, 14(5), 1999, pp. 359-373
Authors:
Krall, WJ
Sramek, JJ
Cutler, NR
Citation: Wj. Krall et al., Cholinesterase inhibitors: A therapeutic strategy for Alzheimer disease, ANN PHARMAC, 33(4), 1999, pp. 441-450
Authors:
Jhee, SS
Salazar, DE
Ford, NF
Fulmor, IE
Sramek, JJ
Cutler, NR
Citation: Ss. Jhee et al., A double-blind, randomized, crossover assessment of blood pressure following administration of avitriptan, sumatriptan, or placebo to patients with mild to moderate hypertension, CEPHALALGIA, 19(2), 1999, pp. 95-99
Authors:
Sramek, JJ
Hourani, J
Jhee, SS
Cutler, NR
Citation: Jj. Sramek et al., NXX-066 in patients with Alzheimer's disease: A bridging study, LIFE SCI, 64(14), 1999, pp. 1215-1221
Authors:
Cutler, NR
Sramek, JJ
Citation: Nr. Cutler et Jj. Sramek, Optimizing the dose for Alzheimer's disease therapeutics: Bridging and dynabridge methodologies, RESEARCH AND PRACTICE IN ALZHEIMER'S DISEASE, VOL 2, 1999, pp. 265-269
Authors:
Cutler, NR
Sramek, JJ
Citation: Nr. Cutler et Jj. Sramek, Optimizing drug development for the next generation of Alzheimer's diseasecompounds, ALZHEIM REP, 1(5), 1998, pp. 285-290
Authors:
Cutler, NR
Sramek, JJ
Citation: Nr. Cutler et Jj. Sramek, Guidelines for conducting bridging studies in Alzheimer disease, ALZ DIS A D, 12(2), 1998, pp. 88-92
Authors:
Sramek, JJ
Eldon, MA
Posvar, EL
Feng, MR
Jhee, SS
Hourani, J
Sedman, AJ
Cutler, NR
Citation: Jj. Sramek et al., Initial safety, tolerability, pharmacodynamics, and pharmacokinetics of Cl-1007 in patients with schizophrenia, PSYCHOPH B, 34(1), 1998, pp. 93-99
Risultati:
1-21
|